Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Accumulated Depreciation & Amortization (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 5 years of Accumulated Depreciation & Amortization data on record, last reported at $10.0 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 37.5% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, down 37.5%, while the annual FY2025 figure was $10.0 million, 37.5% down from the prior year.
  • Accumulated Depreciation & Amortization reached $10.0 million in Q4 2025 per INDV's latest filing, up from $8.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $16.0 million in Q4 2022 and bottomed at $5.0 million in Q1 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $9.5 million, with a median of $8.0 million recorded in 2025.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 166.67% in 2022, then tumbled 37.5% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $6.0 million in 2021, then soared by 166.67% to $16.0 million in 2022, then decreased by 6.25% to $15.0 million in 2023, then rose by 6.67% to $16.0 million in 2024, then crashed by 37.5% to $10.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $10.0 million in Q4 2025, $8.0 million in Q3 2025, and $5.0 million in Q2 2025.